YOLT-101
/ YolTech Therap, Shenzhen Salubris
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
July 14, 2025
YolTech Therapeutics Announces NMPA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
(YolTech Press Release)
- "YolTech Therapeutics...announced that The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has cleared the company’s Investigational New Drug (IND) application for YOLT-101, an in vivo base editing therapy targeting PCSK9 for the treatment of heterozygous familial hypercholesterolemia (HeFH). This marks YOLT-101’s second regulatory clearance-following FDA approval in June 2025-and establishes it as the first in vivo base editing therapy for cardiovascular disease to advance into clinical trials in both the U.S. and China."
New trial • Familial Hypercholesterolemia
June 06, 2025
YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
(The Manila Times)
- "YolTech Therapeutics...announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for YOLT-101, an in vivo base editing therapy targeting PCSK9 for the treatment of heterozygous familial hypercholesterolemia (HeFH)."
IND • Familial Hypercholesterolemia • Heterozygous Familial Hypercholesterolemia
May 01, 2025
Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: RenJi Hospital | N=15 ➔ 20
Enrollment change • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Metabolic Disorders
January 03, 2025
Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)
(clinicaltrials.gov)
- P1 | N=15 | Recruiting | Sponsor: RenJi Hospital | Trial primary completion date: Oct 2025 ➔ Jan 2026
Trial primary completion date • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Metabolic Disorders
June 17, 2024
Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)
(clinicaltrials.gov)
- P1 | N=13 | Recruiting | Sponsor: First Affiliated Hospital Bengbu Medical College
New P1 trial • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Metabolic Disorders
June 13, 2024
Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)
(clinicaltrials.gov)
- P1 | N=7 | Recruiting | Sponsor: RenJi Hospital
New P1 trial • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Metabolic Disorders
1 to 6
Of
6
Go to page
1